[1]
|
Bozkurt, B., Coats, A.J.S., Tsutsui, H., et al. (2021) Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 23.
|
[2]
|
Orso, F., Fabbri, G. and Maggioni, A.P. (2017) Epidemiology of Heart Failure. In: Handbook of Experimental Pharmacology, Vol. 243, Springer, Berlin, 15-33. https://doi.org/10.1007/164_2016_74
|
[3]
|
Bonneux, L., Barendregt, J.J. and Meeter, K. (1994) Estimating Clinical Morbidity Due to Ischemic Heart Disease and Congestive Heart Failure: The Future Rise of Heart Failure. American Journal of Public Health, 84, 20-28.
https://doi.org/10.2105/AJPH.84.1.20
|
[4]
|
Neumiller, J.J., White, J.R. and Campbell, R.K. (2010) Sodium-Glucose Co-Transport Inhibitors Progress and Therapeutic Potential in Type 2 Diabetes Mellitus. Drugs, 70, 377-385. https://doi.org/10.2165/11318680-000000000-00000
|
[5]
|
Sunil, N. and Wilding, J.P.H. (2010) Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism, 95, 34-42.
|
[6]
|
Meng, W., Ellsworth, B.A., Nirschl, A.A., et al. (2008) Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry, 51, 1145-1149. https://doi.org/10.1021/jm701272q
|
[7]
|
McMurray, J.J.V. and Solomon, S.D. (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381, 1995-2008.
|
[8]
|
Kato, E.T., Silverman, M.G., Mosenzon, O., et al. (2019) Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 139, 2528-2536. https://doi.org/10.1161/CIRCULATIONAHA.119.042848
|
[9]
|
Kosiborod, M., Gause-Nilsson, I., Xu, J., et al. (2017) Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes and Concomitant Heart Failure. Journal of Diabetes & Its Complications, 31, 1215-1221.
https://doi.org/10.1016/j.jdiacomp.2017.02.001
|
[10]
|
Petrie, M.C., Verma, S., Docherty, K.F., et al. (2020) Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients with Heart Failure with and without Diabetes. JAMA: The Journal of the American Medical Association, 323, 1353-1368. https://doi.org/10.1001/jama.2019.22087
|
[11]
|
Mcalister, F.A., Ezekowitz, J., Tarantini, L., et al. (2012) Renal Dysfunction in Patients with Heart Failure with Preserved versus Reduced Ejection Fraction: Impact of the New Chronic Kidney Disease-Epidemiology Collaboration Group Formula. Circulation: Heart Failure, 5, 309-314. https://doi.org/10.1161/CIRCHEARTFAILURE.111.966242
|
[12]
|
Jhund, P.S., Solomon, S.D., Docherty, K.F., et al. (2020) Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF. Circulation, 143, 298-309.
|
[13]
|
Tang, H.L., Li, D.D., et al. (2017) Sodium-Glucose Co-Transporter-2 Inhibitors and Risk of Adverse Renal Outcomes among Patients with Type 2 Diabetes: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials. Diabetes, Obesity and Metabolism, 19, 1106-1115.
|
[14]
|
Kohan, D.E., Fioretto, P., Tang, W., et al. (2013) Long-Term Study of Patients with Type 2 Diabetes and Moderate Renal Impairment Shows That Dapagliflozin Reduces Weight and Blood Pressure But Does Not Improve Glycemic Control. Kidney International, 85, 962-971. https://doi.org/10.1038/ki.2013.356
|
[15]
|
Jabbour, S. (2017) Durability of Response to Dapagliflozin: A Review of Long-Term Efficacy and Safety. Current Medical Research & Opinion, 33, 1685-1696. https://doi.org/10.1080/03007995.2017.1354822
|
[16]
|
Tucker, R., Quinn, J.R., Chen, D.G., et al. (2016) Kansas City Cardiomyopathy Questionnaire Administered to Hospitalized Patients with Heart Failure. Journal of Nursing Measurement, 24, 245-257.
https://doi.org/10.1891/1061-3749.24.2.245
|
[17]
|
Green, C.P., Porter, C.B., Bresnahan, D.R., et al. (2000) Development and Evaluation of the Kansas City Cardiomyopathy Questionnaire: A New Health Status Measure for Heart Failure. Journal of the American College of Cardiology, 35, 1245-1255. https://doi.org/10.1016/S0735-1097(00)00531-3
|
[18]
|
Nassif, M.E., Windsor, S.L., Tang, F., et al. (2019) Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction. Circulation, 140, 1463-1476.
https://doi.org/10.1161/CIRCULATIONAHA.119.042929
|
[19]
|
Li, N.J., Guo, L.X., Guo, X.H., et al. (2016) Expert Guidance on Clinical Practice of Sodium Glucose Co-Transporter 2 Inhibitor in China. Chinese Journal of Diabetes.
|
[20]
|
Wilding, J., Woo, V., Rohwedder, K., et al. (2014) Dapagliflozin in Patients with Type 2 Diabetes Receiving High Doses of Insulin: Efficacy and Safety over 2 Years. Diabetes Obesity & Metabolism, 16, 124-136.
https://doi.org/10.1111/dom.12187
|
[21]
|
Wilding, J. (2019) SGLT2 Inhibitors and Urinary Tract Infections. Nature Reviews Endocrinology, 15, 687-688.
https://doi.org/10.1038/s41574-019-0275-6
|